This document addresses the recommendations on the data which should be submitted regarding stability of new dosage forms by the owner of the original application, after the original submission for new active substances and medicinal products.
This document addresses the recommendations on the data which should be submitted regarding stability of new dosage forms by the owner of the original application, after the original submission for new active substances and medicinal products.